DE60023465D1 - Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser - Google Patents

Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser

Info

Publication number
DE60023465D1
DE60023465D1 DE60023465T DE60023465T DE60023465D1 DE 60023465 D1 DE60023465 D1 DE 60023465D1 DE 60023465 T DE60023465 T DE 60023465T DE 60023465 T DE60023465 T DE 60023465T DE 60023465 D1 DE60023465 D1 DE 60023465D1
Authority
DE
Germany
Prior art keywords
active agent
stabilized
formulation
composition
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60023465T
Other languages
English (en)
Other versions
DE60023465T2 (de
Inventor
F Erkoboni
S Vladyka
R Stergios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RP Scherer Technologies LLC
Original Assignee
RP Scherer Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RP Scherer Technologies LLC filed Critical RP Scherer Technologies LLC
Application granted granted Critical
Publication of DE60023465D1 publication Critical patent/DE60023465D1/de
Publication of DE60023465T2 publication Critical patent/DE60023465T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60023465T 1999-03-24 2000-03-20 Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser Expired - Fee Related DE60023465T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12591499P 1999-03-24 1999-03-24
US125914P 1999-03-24
US14968099P 1999-08-19 1999-08-19
US149680P 1999-08-19
PCT/US2000/007298 WO2000056726A1 (en) 1999-03-24 2000-03-20 Improved aqueous solubility pharmaceutical formulations

Publications (2)

Publication Number Publication Date
DE60023465D1 true DE60023465D1 (de) 2005-12-01
DE60023465T2 DE60023465T2 (de) 2006-07-20

Family

ID=26824087

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023465T Expired - Fee Related DE60023465T2 (de) 1999-03-24 2000-03-20 Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser

Country Status (14)

Country Link
US (3) US6497905B1 (de)
EP (1) EP1163234B1 (de)
JP (1) JP2003531099A (de)
CN (1) CN1156461C (de)
AT (1) ATE307808T1 (de)
AU (1) AU3900300A (de)
BR (1) BR0009176A (de)
CA (1) CA2362728C (de)
DE (1) DE60023465T2 (de)
DK (1) DK1163234T3 (de)
ES (1) ES2251985T3 (de)
IL (2) IL145140A0 (de)
TW (1) TWI245644B (de)
WO (1) WO2000056726A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1642571A3 (de) * 2000-12-22 2007-06-27 Baxter International Inc. Herstellungsverfahren für Submikronpartikeln
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
KR20040078661A (ko) * 2002-01-08 2004-09-10 캔 테크놀로지스 인코포레이티드 소수성 고융점 화합물 및 지질의 혼합물로의 코팅에 의한캡슐화
ZA200502496B (en) 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP1594467A4 (de) 2002-07-05 2008-10-22 Collegium Pharmaceutical Inc Missbrauch verhindernde pharmazeutische zusammensetzungen von opioiden und anderen medikamenten
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
MXPA06000178A (es) * 2003-07-01 2006-04-11 Pharmacia & Upjohn Co Llc Solidos modulados en la fase de difusion.
HU227142B1 (en) * 2003-07-02 2010-08-30 Egis Gyogyszergyar Nyilvanosan Capsule of improved release containing fluconazole
EP1651195A4 (de) * 2003-07-11 2007-10-03 Myriad Genetics Inc Pharmazeutische verfahren, dosierschemata und dosierformen zur behandlung von alzheimerkrankheit
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP1669345A4 (de) 2003-08-29 2008-02-20 Japan Tobacco Inc Esterderivate und deren medizinische verwendung
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
JP2007308479A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
EP2334845A2 (de) * 2008-10-06 2011-06-22 Katholieke Universiteit Leuven K.U. Leuven R&D Funktionelle schichten von biomolekülen und lebenden zellen und neues system zu ihrer herstellung
EP2376068A2 (de) 2008-12-15 2011-10-19 Banner Pharmacaps, Inc. Verfahren zur verbesserung der freisetzung und absorption von wasserunl?slichen wirkstoffen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2515879A4 (de) * 2009-12-22 2014-04-02 Fmc Corp Inc Feinpartikel-croscarmellose und ihre verwendungen
EP2601973A1 (de) * 2011-12-09 2013-06-12 Laboratoires SMB SA Trockenpulverformulierung eines Azolderivats zum Inhalieren
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
GB201602579D0 (en) * 2016-02-12 2016-03-30 Mihranyan Albert New compositions
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5118799A (en) 1987-05-12 1992-06-02 Pharmacin Corporation Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate
EP0462066A1 (de) 1990-06-15 1991-12-18 Warner-Lambert Company Amorphes Gemfibrozil
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5208015A (en) 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
US5200195A (en) 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
WO1993015719A1 (en) 1992-02-12 1993-08-19 Janssen Farmaceutici S.P.A. Liposomal itraconazole formulations
PT631578E (pt) 1992-03-18 2001-11-30 Janssen Pharmaceutica Nv Estereoisomeros de itraconazol e saperconazol
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5976555A (en) * 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP3310299B2 (ja) 1995-11-23 2002-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 溶融−押し出しにより調製されるシクロデキストリンの固体混合物
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
EP0904060B1 (de) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
RU2218153C2 (ru) 1997-03-26 2003-12-10 Жансен Фармасетика Н.В. Драже, имеющее ядро, покрытое противогрибковым средством и полимером
US5813416A (en) 1997-04-03 1998-09-29 Rudolph; James M. File with sanitizing agent
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제

Also Published As

Publication number Publication date
ATE307808T1 (de) 2005-11-15
CA2362728A1 (en) 2000-09-28
JP2003531099A (ja) 2003-10-21
EP1163234A1 (de) 2001-12-19
BR0009176A (pt) 2001-12-18
CN1379768A (zh) 2002-11-13
TWI245644B (en) 2005-12-21
EP1163234A4 (de) 2003-05-02
US6511681B2 (en) 2003-01-28
AU3900300A (en) 2000-10-09
US6497905B1 (en) 2002-12-24
DE60023465T2 (de) 2006-07-20
DK1163234T3 (da) 2006-02-27
ES2251985T3 (es) 2006-05-16
WO2000056726A1 (en) 2000-09-28
US20020037324A1 (en) 2002-03-28
CN1156461C (zh) 2004-07-07
CA2362728C (en) 2009-06-23
US20020012706A1 (en) 2002-01-31
IL145140A (en) 2006-08-20
US6379707B2 (en) 2002-04-30
EP1163234B1 (de) 2005-10-26
IL145140A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
PE20001049A1 (es) Complejos estables de compuestos escasamente solubles
ITMI20021392A1 (it) Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
ES2193658T3 (es) Procedimiento para la preparacion de formulaciones acuosas para uso oftalmico.
YU23599A (sh) Stabilizovani antihistaminski sirup
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
CA2414063A1 (en) Highly concentrated stable meloxicam solutions
MXPA05005046A (es) Formulaciones parasiticidas topicas y metodos de tratamiento.
DE60017361D1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
MXPA02001804A (es) Composicion para inhalacion que comprende delta-9-tetrahidrocanabinol en un solvente semi-acuoso.
CA2380757A1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
PE20030545A1 (es) Formulaciones de jarabe de ribavirina
ATE245968T1 (de) Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
EP1219296A4 (de) Mittel zur hemmung der sebumproduktion
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
ATE275577T1 (de) Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
ATE258046T1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
WO2005123085A1 (es) Solución acuosa de risperidona para administración oral

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee